Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Kluge AF, Patane MA, Van Drie JH, Wang C, McElligott D, Kesicki EA, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD.

Nature. 2018 Jun;558(7710):E1. doi: 10.1038/s41586-018-0111-5.

PMID:
29769713
2.

Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.

Michaelides MR, Kluge A, Patane M, Van Drie JH, Wang C, Hansen TM, Risi RM, Mantei R, Hertel C, Karukurichi K, Nesterov A, McElligott D, de Vries P, Langston JW, Cole PA, Marmorstein R, Liu H, Lasko L, Bromberg KD, Lai A, Kesicki EA.

ACS Med Chem Lett. 2017 Dec 13;9(1):28-33. doi: 10.1021/acsmedchemlett.7b00395. eCollection 2018 Jan 11.

3.

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E, Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston JW, Weinert BT, Choudhary C, de Vries P, Van Drie JH, McElligott D, Kesicki E, Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD.

Nature. 2017 Oct 5;550(7674):128-132. doi: 10.1038/nature24028. Epub 2017 Sep 27. Erratum in: Nature. 2018 May 16;:.

4.

Protein folding, protein homeostasis, and cancer.

Van Drie JH.

Chin J Cancer. 2011 Feb;30(2):124-37. Review.

5.

Navigating structure-activity landscapes.

Bajorath J, Peltason L, Wawer M, Guha R, Lajiness MS, Van Drie JH.

Drug Discov Today. 2009 Jul;14(13-14):698-705. doi: 10.1016/j.drudis.2009.04.003. Epub 2009 May 3. Review.

PMID:
19410012
6.

Assessing how well a modeling protocol captures a structure-activity landscape.

Guha R, Van Drie JH.

J Chem Inf Model. 2008 Aug;48(8):1716-28. doi: 10.1021/ci8001414. Epub 2008 Aug 8.

PMID:
18686944
7.

Structure--activity landscape index: identifying and quantifying activity cliffs.

Guha R, Van Drie JH.

J Chem Inf Model. 2008 Mar;48(3):646-58. doi: 10.1021/ci7004093. Epub 2008 Feb 28.

PMID:
18303878
8.

Computer-aided drug design: the next 20 years.

Van Drie JH.

J Comput Aided Mol Des. 2007 Oct-Nov;21(10-11):591-601. Epub 2007 Nov 8.

PMID:
17989929
9.

Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.

Perni RB, Farmer LJ, Cottrell KM, Court JJ, Courtney LF, Deininger DD, Gates CA, Harbeson SL, Kim JL, Lin C, Lin K, Luong YP, Maxwell JP, Murcko MA, Pitlik J, Rao BG, Schairer WC, Tung RD, Van Drie JH, Wilson K, Thomson JA.

Bioorg Med Chem Lett. 2004 Apr 19;14(8):1939-42.

PMID:
15050632
10.

Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.

Perni RB, Pitlik J, Britt SD, Court JJ, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Levin RB, Lin C, Lin K, Moon YC, Luong YP, O'Malley ET, Rao BG, Thomson JA, Tung RD, Van Drie JH, Wei Y.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1441-6.

PMID:
15006379
11.

Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.

Perni RB, Britt SD, Court JC, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Kim JL, Landro JA, Levin RB, Luong YP, O'Malley ET, Pitlik J, Rao BG, Schairer WC, Thomson JA, Tung RD, Van Drie JH, Wei Y.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):4059-63.

PMID:
14592508
12.

Pharmacophore discovery--lessons learned.

van Drie JH.

Curr Pharm Des. 2003;9(20):1649-64. Review.

PMID:
12871063
13.

Structure-based design of combinatorial libraries.

van Drie JH, Rohrer DC, Blinn JR, Gao H.

EXS. 2003;(93):203-21. Review. No abstract available.

PMID:
12613178
14.

The constituent tryptophans and bisANS as fluorescent probes of the active site and of a secondary binding site of stromelysin-1 (MMP-3).

Epps DE, Poorman RA, Petzold GL, Stuchly CW, Laborde AL, Van Drie JH.

J Protein Chem. 1998 Oct;17(7):699-712.

PMID:
9853686
15.

Strategies for the determination of pharmacophoric 3D database queries.

Van Drie JH.

J Comput Aided Mol Des. 1997 Jan;11(1):39-52.

PMID:
9139111
16.
17.

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck DW, Plattner JJ, Rittenhouse JW, Turon M, Wideburg N, et al.

Science. 1990 Aug 3;249(4968):527-33.

PMID:
2200122
19.

Strategies in drug design based on 3D-structures of ligands.

Martin YC, Danaher EB, May CS, Weininger D, Van Drie JH.

Prog Clin Biol Res. 1989;291:177-81. No abstract available.

PMID:
2726842

Supplemental Content

Loading ...
Support Center